COVID-19-Associated Carotid Atherothrombosis and Stroke

References

1. 1.↵
   1. Barnett HJ,
   2. Taylor DW,
   3. Haynes RB, et al

   ; North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445–53 doi:10.1056/NEJM199108153250701 pmid:1852179

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Fisher CM

   . Transient monocular blindness associated with hemiplegia. AMA Arch Ophthalmol 1952;47:167–203 doi:10.1001/archopht.1952.01700030174005 pmid:14894017

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Esenwa CC,
   2. Elkind MS

   . Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. Nat Rev Neurol 2016;12:594–604 doi:10.1038/nrneurol.2016.125 pmid:27615422

   CrossRefPubMed
4. 4.↵
   1. Clerkin KJ,
   2. Fried JA,
   3. Raikhelkar J, et al

   . Coronavirus disease 2019 (Covid-19) and cardiovascular disease. Circulation 2020;141:1648–55 doi:10.1161/CIRCULATIONAHA.120.046941

   CrossRefPubMed
5. 5.↵
   1. Oxley TJ,
   2. Mocco J,
   3. Majidi S, et al

   . Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 2020;382:e60 doi:10.1056/NEJMc2009787 pmid:32343504

   CrossRefPubMed
6. 6.↵
   1. Wang A,
   2. Mandigo GK,
   3. Yim PD, et al

   . Stroke and mechanical thrombectomy in patients with COVID-19: technical observations and patient characteristics. J Neurointerv Surg 2020;12:648–53 doi:10.1136/neurintsurg-2020-016220 pmid:32451359

   Abstract/FREE Full Text
7. 7.↵
   1. Hoffmann M,
   2. Kleine-Weber H,
   3. Schroeder S, et al

   . SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271–80.e278 doi:10.1016/j.cell.2020.02.052 pmid:32142651

   CrossRefPubMed
8. 8.↵
   1. Tikellis C,
   2. Thomas MC

   . Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept 2012;2012:256294 doi:10.1155/2012/256294 pmid:22536270

   CrossRefPubMed
9. 9.↵
   1. Varga Z,
   2. Flammer AJ,
   3. Steiger P, et al

   . Endothelial cell infection and endotheliitis in Covid-19. Lancet 2020;395:1417–18 doi:10.1016/S0140-6736(20)30937-5 pmid:32325026

   CrossRefPubMed
10. 10.↵
    1. Buja LM,
    2. Wolf DA,
    3. Zhao B, et al

    . The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc Pathol 2020;48:107233 doi:10.1016/j.carpath.2020.107233 pmid:32434133

    CrossRefPubMed
11. 11.↵
    1. Connors J,
    2. Levy J

    . Covid-19 and its implications for thrombosis and anticoagulation. Blood 2020;135:2033–40 doi:10.1182/blood.2020006000 pmid:32339221

    CrossRefPubMed
12. 12.↵
    1. Magro C,
    2. Mulvey JJ,
    3. Berlin D, et al

    . Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020;220:1–13 doi:10.1016/j.trsl.2020.04.007 pmid:32299776

    CrossRefPubMed
13. 13.↵
    1. Carsana L,
    2. Sonzogni A,
    3. Nasr A, et al

    . Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020 June 8. [Epub ahead of print] doi:10.1016/S1473-3099(20)30434-5 pmid:32526193

    CrossRefPubMed
14. 14.↵
    1. Connors JM,
    2. Levy JH

    . Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost 2020;18:1559–61 doi:10.1111/jth.14849 pmid:32302453

    CrossRefPubMed
15. 15.↵
    1. Jackson SP,
    2. Darbousset R,
    3. Schoenwaelder SM

    . Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood 2019;133:906–18 doi:10.1182/blood-2018-11-882993 pmid:30642917

    Abstract/FREE Full Text